O	0	6	Impact
O	7	9	of
B-intervention	10	19	aromatase
I-intervention	20	29	inhibitor
I-intervention	30	39	treatment
O	40	42	on
O	43	49	global
O	50	54	gene
O	55	65	expression
O	66	69	and
O	70	73	its
O	74	85	association
O	86	90	with
O	91	108	antiproliferative
O	109	117	response
O	118	120	in
O	121	123	ER
O	123	124	+
O	125	131	breast
O	132	138	cancer
O	139	141	in
O	142	156	postmenopausal
O	157	165	patients
O	165	166	.

O	167	176	Endocrine
O	177	184	therapy
O	185	192	reduces
O	193	199	breast
O	200	206	cancer
O	207	216	mortality
O	217	219	by
O	220	222	40
O	222	223	%
O	223	224	,
O	225	228	but
O	229	239	resistance
O	240	247	remains
O	248	249	a
O	250	255	major
O	256	264	clinical
O	265	272	problem
O	272	273	.

O	274	276	In
O	277	281	this
O	282	287	study
O	287	288	,
O	289	291	we
O	292	298	sought
O	299	301	to
O	302	313	investigate
O	314	317	the
O	318	324	impact
O	325	327	of
O	328	337	aromatase
O	338	347	inhibitor
O	348	349	(
O	349	351	AI
O	351	352	)
O	353	360	therapy
O	361	363	on
O	364	368	gene
O	369	379	expression
O	380	383	and
O	384	392	identify
O	393	397	gene
O	398	405	modules
O	406	418	representing
O	419	422	key
O	423	433	biological
O	434	442	pathways
O	443	447	that
O	448	454	relate
O	455	457	to
O	458	463	early
O	464	466	AI
O	467	474	therapy
O	475	485	resistance
O	485	486	.

O	487	493	Global
O	494	498	gene
O	499	509	expression
O	510	513	was
O	514	522	measured
O	523	525	on
O	526	531	pairs
O	532	534	of
O	535	539	core
O	539	540	-
O	540	543	cut
O	544	552	biopsies
O	553	558	taken
O	559	561	at
O	562	570	baseline
O	571	574	and
O	575	577	at
O	578	585	surgery
O	586	590	from
B-total-participants	591	594	254
B-eligibility	595	603	patients
I-eligibility	604	608	with
I-eligibility	609	611	ER
I-eligibility	611	612	-
I-eligibility	612	620	positive
I-eligibility	621	628	primary
I-eligibility	629	635	breast
I-eligibility	636	642	cancer
O	643	653	randomised
O	654	656	to
O	657	664	receive
O	665	666	2
O	666	667	-
O	667	671	week
O	672	683	presurgical
O	684	686	AI
O	687	688	(
O	688	689	n
O	690	691	=
B-intervention-participants	692	695	198
O	695	696	)
O	697	699	or
B-control	700	702	no
I-control	703	714	presurgical
I-control	715	724	treatment
O	725	726	(
O	726	733	control
O	734	735	n
O	736	737	=
B-control-participants	738	740	56
O	740	741	)
O	742	746	from
O	747	750	the
O	751	757	POETIC
O	758	763	trial
O	763	764	.

O	765	769	Data
O	770	774	from
O	775	778	the
O	779	781	AI
O	782	787	group
O	788	791	was
O	792	800	adjusted
O	801	803	to
O	804	813	eliminate
O	814	825	artefactual
O	826	833	process
O	833	834	-
O	834	841	related
O	842	849	changes
O	850	860	identified
O	861	863	in
O	864	867	the
O	868	875	control
O	876	881	group
O	881	882	.

O	883	886	The
O	887	895	response
O	896	899	was
O	900	908	assessed
O	909	911	by
O	912	919	changes
O	920	922	in
O	923	926	the
O	927	940	proliferation
O	941	947	marker
O	947	948	,
O	949	953	Ki67
O	953	954	.

O	955	959	High
B-outcome	960	968	baseline
I-outcome	969	973	ESR1
I-outcome	974	984	expression
O	985	995	associated
O	996	1000	with
O	1001	1007	better
O	1008	1010	AI
O	1011	1019	response
O	1020	1022	in
O	1023	1027	HER2
O	1027	1028	+
O	1029	1036	tumours
O	1037	1040	but
O	1041	1044	not
O	1045	1049	HER2
O	1049	1050	-
O	1051	1058	tumours
O	1058	1059	.

O	1060	1062	In
O	1063	1067	HER2
O	1067	1068	-
O	1069	1076	tumours
O	1076	1077	,
B-outcome	1078	1086	baseline
I-outcome	1087	1097	expression
I-outcome	1098	1100	of
I-outcome	1101	1103	48
I-outcome	1104	1109	genes
O	1110	1120	associated
O	1121	1125	with
O	1126	1130	poor
O	1131	1148	antiproliferative
O	1149	1157	response
O	1158	1159	(
O	1159	1160	p
O	1161	1162	<
O	1163	1164	0
O	1164	1165	.
O	1165	1168	005
O	1168	1169	)
O	1170	1179	including
O	1180	1184	PERP
O	1185	1188	and
O	1189	1194	YWHAQ
O	1194	1195	,
O	1196	1199	the
O	1200	1203	two
O	1204	1208	most
O	1209	1220	significant
O	1220	1221	,
O	1222	1225	and
O	1226	1229	the
O	1230	1243	transcription
O	1244	1246	co
O	1246	1247	-
O	1247	1257	regulators
O	1258	1259	(
O	1259	1265	SAP130
O	1265	1266	,
O	1267	1272	HDAC4
O	1272	1273	,
O	1274	1277	and
O	1278	1283	NCOA7
O	1283	1284	)
O	1285	1290	which
O	1291	1295	were
O	1296	1301	among
O	1302	1305	the
O	1306	1309	top
O	1310	1312	16
O	1313	1317	most
O	1318	1329	significant
O	1329	1330	.

O	1331	1339	Baseline
O	1340	1344	gene
O	1345	1354	signature
O	1355	1361	scores
O	1362	1371	measuring
O	1372	1376	cell
O	1377	1390	proliferation
O	1390	1391	,
O	1392	1398	growth
O	1399	1405	factor
O	1406	1416	signalling
O	1417	1418	(
O	1418	1423	ERBB2
O	1423	1424	-
O	1424	1426	GS
O	1426	1427	,
O	1428	1431	RET
O	1431	1432	/
O	1432	1436	GDNF
O	1436	1437	-
O	1437	1439	GS
O	1439	1440	,
O	1441	1444	and
O	1445	1448	IGF
O	1448	1449	-
O	1449	1450	1
O	1450	1451	-
O	1451	1453	GS
O	1453	1454	)
O	1454	1455	,
O	1456	1459	and
O	1460	1466	immune
O	1467	1475	activity
O	1476	1477	(
O	1477	1482	STAT1
O	1482	1483	-
O	1483	1485	GS
O	1485	1486	)
O	1487	1491	were
O	1492	1505	significantly
O	1506	1512	higher
O	1513	1515	in
O	1516	1520	poor
O	1521	1523	AI
O	1524	1534	responders
O	1534	1535	.

O	1536	1539	Two
O	1540	1545	weeks
O	1546	1548	of
O	1549	1551	AI
O	1552	1558	caused
B-outcome	1559	1573	downregulation
I-outcome	1574	1576	of
I-outcome	1577	1582	genes
I-outcome	1583	1591	involved
I-outcome	1592	1594	in
I-outcome	1595	1599	cell
I-outcome	1600	1613	proliferation
I-outcome	1614	1617	and
I-outcome	1618	1620	ER
I-outcome	1621	1631	signalling
O	1631	1632	,
O	1633	1635	as
O	1636	1644	expected
O	1644	1645	.

B-outcome	1646	1655	Signature
I-outcome	1656	1662	scores
I-outcome	1663	1665	of
I-outcome	1666	1669	E2F
I-outcome	1670	1680	activation
I-outcome	1681	1684	and
I-outcome	1685	1689	TP53
I-outcome	1690	1701	dysfunction
O	1702	1707	after
O	1708	1709	2
O	1709	1710	-
O	1710	1714	week
O	1715	1717	AI
O	1718	1722	were
O	1723	1733	associated
O	1734	1738	with
O	1739	1743	poor
O	1744	1746	AI
O	1747	1755	response
O	1756	1758	in
O	1759	1763	both
O	1764	1768	HER2
O	1768	1769	-
O	1770	1773	and
O	1774	1778	HER2
O	1778	1779	+
O	1780	1788	patients
O	1788	1789	.

O	1790	1795	There
O	1796	1798	is
O	1799	1800	a
O	1801	1805	high
B-outcome	1806	1812	degree
I-outcome	1813	1815	of
I-outcome	1816	1829	heterogeneity
O	1830	1832	in
O	1833	1841	adaptive
O	1842	1852	mechanisms
O	1853	1858	after
O	1859	1861	as
O	1862	1868	little
O	1869	1871	as
O	1872	1873	2
O	1873	1874	-
O	1874	1878	week
O	1879	1881	AI
O	1882	1889	therapy
O	1889	1890	;
O	1891	1898	however
O	1898	1899	,
O	1900	1903	all
O	1904	1910	appear
O	1911	1913	to
O	1914	1922	converge
O	1923	1925	on
O	1926	1930	cell
O	1931	1936	cycle
O	1937	1947	regulation
O	1947	1948	.

O	1949	1952	Our
O	1953	1957	data
O	1958	1965	support
O	1966	1969	the
O	1970	1980	evaluation
O	1981	1983	of
O	1984	1991	whether
O	1992	1994	an
O	1995	1998	E2F
O	1999	2009	signatures
O	2010	2015	after
O	2016	2021	short
O	2021	2022	-
O	2022	2026	term
O	2027	2035	exposure
O	2036	2038	to
O	2039	2041	AI
O	2042	2045	may
O	2046	2054	identify
O	2055	2060	those
O	2061	2069	patients
O	2070	2074	most
O	2075	2081	likely
O	2082	2084	to
O	2085	2092	benefit
O	2093	2097	from
O	2098	2101	the
O	2102	2107	early
O	2108	2116	addition
O	2117	2119	of
O	2120	2124	CDK4
O	2124	2125	/
O	2125	2126	6
O	2127	2137	inhibitors
O	2137	2138	.

O	2139	2145	ISRCTN
O	2145	2146	,
O	2147	2161	ISRCTN63882543
O	2161	2162	,
O	2163	2173	registered
O	2174	2176	on
O	2177	2179	18
O	2180	2188	December
O	2189	2193	2007
O	2193	2194	.
